Trials / Completed
CompletedNCT01281917
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University of Wisconsin, Madison · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Velcade | Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22) |
| DRUG | Temsirolimus | Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29) |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2013-10-01
- Completion
- 2014-06-01
- First posted
- 2011-01-24
- Last updated
- 2019-12-13
- Results posted
- 2017-08-21
Locations
18 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01281917. Inclusion in this directory is not an endorsement.